Clinical issues related to depression in schizophrenia: an international survey of psychiatrists

被引:41
作者
Addington, DD
Azorin, JM
Falloon, IBH
Gerlach, J
Hirsch, SR
Siris, SG
机构
[1] CHU St Marguerite, Marseille, France
[2] Univ Auckland, Auckland 1, New Zealand
[3] St Hans Hosp, Roskilde, Denmark
[4] Charing Cross & Westminster Med Sch, London, England
[5] Albert Einstein Coll Med, New York, NY USA
[6] Foothills Prov Gen Hosp, Dept Psychiat, Calgary, AB T2N 2T9, Canada
关键词
antidepressive agents; antipsychotic agents; depression; electroconvulsive therapy; patient care management; schizophrenia;
D O I
10.1034/j.1600-0447.2002.1o458.x
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: Depressive symptoms in schizophrenia are associated with a substantial morbidity and mortality burden. The 'International Survey of Depression in Schizophrenia' was designed to evaluate current awareness and clinical approaches in this area. Method: A 48-item questionnaire was distributed to approximately 80 000 consultant psychiatrists world-wide. Responses were analysed using descriptive statistics. Results: Respondents demonstrated considerable awareness of the prevalence and consequences of depression in schizophrenia. Although there was widespread adjunctive use of antidepressants. one-third of respondents indicated that they rarely or never prescribe these agents in combination with antipsychotic medication. There were considerable variations in opinions about the best approach to the treatment of depressive symptoms associated with schizophrenia. Conclusion: The considerable clinical burden of depressive symptomatology in schizophrenia was acknowledged by the majority of respondents to this survey. There was, however, little agreement on the best management strategy.
引用
收藏
页码:189 / 195
页数:7
相关论文
共 23 条
[1]   Response rates to mail surveys published in medical journals [J].
Asch, DA ;
Jedrziewski, MK ;
Christakis, NA .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1997, 50 (10) :1129-1136
[2]   Prevalence and background factors of depression in first admitted schizophrenic patients [J].
Bottlender, R ;
Strauss, A ;
Möller, HJ .
ACTA PSYCHIATRICA SCANDINAVICA, 2000, 101 (02) :153-160
[3]   COMPARATIVE CONTROLLED TRIAL OF PIMOZIDE AND FLUPHENAZINE DECANOATE IN CONTINUATION THERAPY OF SCHIZOPHRENIA [J].
FALLOON, I ;
WATT, DC ;
SHEPHERD, M .
PSYCHOLOGICAL MEDICINE, 1978, 8 (01) :59-70
[4]   DEPRESSION AND SOCIAL-ADJUSTMENT AMONG CHRONIC-SCHIZOPHRENIC OUTPATIENTS [J].
GLAZER, W ;
PRUSOFF, B ;
JOHN, K ;
WILLIAMS, D .
JOURNAL OF NERVOUS AND MENTAL DISEASE, 1981, 169 (11) :712-717
[5]   A SURVEY OF PRACTICING PSYCHIATRISTS VIEWS ON THE TREATMENT OF AGORAPHOBIA [J].
HALL, W ;
WEEKES, P ;
HARVEY, R ;
ANDREWS, G .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 1982, 16 (04) :225-233
[6]  
HERZ M, 1985, J CLIN PSYCHIAT, V46, P22
[7]  
Herz MI, 1997, AM J PSYCHIAT, V154, P1
[8]  
HOFMANN P, 1997, INT PSYCHIAT TODAY, V7, P1
[9]  
Kaner EF, 1998, BRIT J GEN PRACT, V48, P1067
[10]  
LEFF J, 1990, PROG PSYCH, P3